The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Metabolic and Atherosclerosis Research Center
Cincinnati, Ohio, United States
Lipid Clinic and Community Genomic Center, Complexe Hospitalier de la Sagamie
Chicoutimi, Quebec, Canada
Lipid Research Center, CHUL du CHUQ
Sainte-Foy, Quebec, Canada
Hadassah University Hospital
Jerusalem, Israel
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Academic Medical Center Amsterdam
Amsterdam, Netherlands
Lipidklinikken - Rikshospitalet
Oslo, Norway